News | June 08, 2008

Atrium Launches Voclosporin-Coated Stent Implant Trial

June 9, 2008 - Atrium Medical has begun enrollment of the first patients for their CONFIRM 1, First-in-Man (FIM) drug-eluting coronary stent clinical trial designed to evaluate the safety and performance of the stent.

The CINATRA voclosporin coated coronary stent system is a cobalt chromium balloon expandable stent, with a nonpolymer coating platform, mounted on a low profile rapid exchange catheter. Atrium's stent and balloon are both coated with Atrium's proprietary Omega 3 fatty acid coating technology, providing a more uniform bio-absorbable delivery vehicle for its anti-inflammatory compound, voclosporin.

This First-in-Man trial is a prospective, multicenter, single blind, randomized, controlled study using the CINATRA voclosporin coated coronary stent system, which will be compared to Atrium’s CINATRA bare metal coronary stent (BMS) platform.

This first use study of voclosporin on an implantable medical device will enroll 100 patients, and will be conducted at seven hospitals in Belgium with Glenn Van Langenhove, M.D., PhD, of Middelheim Hospital, Antwerp, as the study's principal investigator. The primary endpoint of the trial is to evaluate the safety and performance of the CINATRA voclosporin coated coronary stent system and the CINATRA BMS coronary stent system in patients with de novo coronary artery disease. Clinicians will assess patient outcomes, in addition to drug coated stent performance, by measuring late lumen loss, in-stent and in-segment lumen loss measurements at six months following implantation.

For more information: www.atriummed.com

Related Content

News | Stents Drug Eluting

June 2, 2022 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced print ...

Home June 02, 2022
Home
News | Stents Drug Eluting

February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...

Home February 16, 2022
Home
News | Stents Drug Eluting

January 26, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's Synergy Megatron Drug ...

Home January 26, 2021
Home
Videos | Stents Drug Eluting

Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ ...

Home October 19, 2020
Home
News | Stents Drug Eluting

October 16, 2020 – Results from the XIENCE 90/28 clinical trials have shown that a shorter course of dual-antiplatelet ...

Home October 16, 2020
Home
News | Stents Drug Eluting

October 11, 2019 — The ultra-thin Supraflex drug-eluting stent (DES) from SMT maintained numerically lower outcomes at ...

Home October 11, 2019
Home
News | Stents Drug Eluting

September 30, 2019 – The first randomized trial to compare a durable polymer drug-eluting stent to a polymer-free drug ...

Home September 30, 2019
Home
News | Stents Drug Eluting

September 30, 2019 — A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual ...

Home September 30, 2019
Home
News | Stents Drug Eluting

September 5, 2019 — Biotronik's ultrathin Orsiro stent demonstrated superiority over Xience with respect to target ...

Home September 05, 2019
Home
News | Stents Drug Eluting

October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer ...

Home October 01, 2018
Home
Subscribe Now